Impact of Preoperative Chemotherapy Features on Patient Outcomes after Hepatectomy for Initially Unresectable Colorectal Cancer Liver Metastases: A LiverMetSurvey Analysis

Simple Summary The features of preoperative systemic anticancer therapy associated with best outcomes after resection of initially-irresectable liver metastases from colorectal cancer are yet to be identified. We harnessed data from a prospective international surgical database (LiverMetSurvey) to e...

Descripción completa

Detalles Bibliográficos
Autores: Innominato, PF, Cailliez, V, Allard, MA, Lopez-Ben, S, Ferrero, A, Marques, H, Hubert, C, Giuliante, F, Pereira, F, Cugat, E, Mirza, DF, Costa-Maia, J, Serrablo, A, Lapointe, R, Dopazo, C, Tralhao, J, Kaiser, G, Chen, JS, Garcia-Borobia, F, Regimbeau, JM, Skipenko, O, Lin, JK, Laurent, C, Opocher, E, Goto, Y, Chibaudel, B, de Gramont, A, Adam, R
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Institut d'Investigació i Innovació Parc Taulí (I3PT)
Repositorio:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
OAI Identifier:oai:i3pt.fundanetsuite.com:p1260
Acceso en línea:https://i3pt.portalinvestigacion.com/publicaciones/1260
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85137942737&doi=10.3390%2fcancers14174340&partnerID=40&md5=df8379f0a2b3fbb33fa86cf11cb98b00
Access Level:acceso abierto
Palabra clave:colorectal cancer
liver metastases
hepatectomy
neo-adjuvant chemotherapy
preoperative chemotherapy
onco-surgical approach
liver resection
LiverMetSurvey
real-world evidence
downsizing
irresectable hepatic metastases
id ES_63df35a28a169a8a66053ef067a85cb2
oai_identifier_str oai:i3pt.fundanetsuite.com:p1260
network_acronym_str ES
network_name_str España
repository_id_str
dc.title.none.fl_str_mv Impact of Preoperative Chemotherapy Features on Patient Outcomes after Hepatectomy for Initially Unresectable Colorectal Cancer Liver Metastases: A LiverMetSurvey Analysis
title Impact of Preoperative Chemotherapy Features on Patient Outcomes after Hepatectomy for Initially Unresectable Colorectal Cancer Liver Metastases: A LiverMetSurvey Analysis
spellingShingle Impact of Preoperative Chemotherapy Features on Patient Outcomes after Hepatectomy for Initially Unresectable Colorectal Cancer Liver Metastases: A LiverMetSurvey Analysis
Innominato, PF
colorectal cancer
liver metastases
hepatectomy
neo-adjuvant chemotherapy
preoperative chemotherapy
onco-surgical approach
liver resection
LiverMetSurvey
real-world evidence
downsizing
irresectable hepatic metastases
title_short Impact of Preoperative Chemotherapy Features on Patient Outcomes after Hepatectomy for Initially Unresectable Colorectal Cancer Liver Metastases: A LiverMetSurvey Analysis
title_full Impact of Preoperative Chemotherapy Features on Patient Outcomes after Hepatectomy for Initially Unresectable Colorectal Cancer Liver Metastases: A LiverMetSurvey Analysis
title_fullStr Impact of Preoperative Chemotherapy Features on Patient Outcomes after Hepatectomy for Initially Unresectable Colorectal Cancer Liver Metastases: A LiverMetSurvey Analysis
title_full_unstemmed Impact of Preoperative Chemotherapy Features on Patient Outcomes after Hepatectomy for Initially Unresectable Colorectal Cancer Liver Metastases: A LiverMetSurvey Analysis
title_sort Impact of Preoperative Chemotherapy Features on Patient Outcomes after Hepatectomy for Initially Unresectable Colorectal Cancer Liver Metastases: A LiverMetSurvey Analysis
dc.creator.none.fl_str_mv Innominato, PF
Cailliez, V
Allard, MA
Lopez-Ben, S
Ferrero, A
Marques, H
Hubert, C
Giuliante, F
Pereira, F
Cugat, E
Mirza, DF
Costa-Maia, J
Serrablo, A
Lapointe, R
Dopazo, C
Tralhao, J
Kaiser, G
Chen, JS
Garcia-Borobia, F
Regimbeau, JM
Skipenko, O
Lin, JK
Laurent, C
Opocher, E
Goto, Y
Chibaudel, B
de Gramont, A
Adam, R
author Innominato, PF
author_facet Innominato, PF
Cailliez, V
Allard, MA
Lopez-Ben, S
Ferrero, A
Marques, H
Hubert, C
Giuliante, F
Pereira, F
Cugat, E
Mirza, DF
Costa-Maia, J
Serrablo, A
Lapointe, R
Dopazo, C
Tralhao, J
Kaiser, G
Chen, JS
Garcia-Borobia, F
Regimbeau, JM
Skipenko, O
Lin, JK
Laurent, C
Opocher, E
Goto, Y
Chibaudel, B
de Gramont, A
Adam, R
author_role author
author2 Cailliez, V
Allard, MA
Lopez-Ben, S
Ferrero, A
Marques, H
Hubert, C
Giuliante, F
Pereira, F
Cugat, E
Mirza, DF
Costa-Maia, J
Serrablo, A
Lapointe, R
Dopazo, C
Tralhao, J
Kaiser, G
Chen, JS
Garcia-Borobia, F
Regimbeau, JM
Skipenko, O
Lin, JK
Laurent, C
Opocher, E
Goto, Y
Chibaudel, B
de Gramont, A
Adam, R
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv colorectal cancer
liver metastases
hepatectomy
neo-adjuvant chemotherapy
preoperative chemotherapy
onco-surgical approach
liver resection
LiverMetSurvey
real-world evidence
downsizing
irresectable hepatic metastases
topic colorectal cancer
liver metastases
hepatectomy
neo-adjuvant chemotherapy
preoperative chemotherapy
onco-surgical approach
liver resection
LiverMetSurvey
real-world evidence
downsizing
irresectable hepatic metastases
description Simple Summary The features of preoperative systemic anticancer therapy associated with best outcomes after resection of initially-irresectable liver metastases from colorectal cancer are yet to be identified. We harnessed data from a prospective international surgical database (LiverMetSurvey) to explore the duration and modalities of preoperative systemic anticancer therapy associated with longer overall survival in this clinical setting. Our study included 2793 patients having undergone liver surgery after preoperative systemic anticancer treatment for initially irresectable disease. We found that short (<7 or <13 cycles in 1st or 2nd line, respectively) duration was associated with longer survival outcomes, independently from other prognostic factors. Conversely, all the comparisons between different conventional active regimens displayed similar results. Our findings support the recommended onco-surgical approach of aiming at performing liver surgery as soon as technically feasible after response to preoperative systemic anticancer therapy in hepatic metastases from colorectal cancer, initially not amenable to surgery. The results of this study also suggest that, provided the systemic anticancer therapy regimen is active, the choice of the drugs used bears overall little if any impact on the outcomes. Background: Prognostic factors have been extensively reported after resection of colorectal liver metastases (CLM); however, specific analyses of the impact of preoperative systemic anticancer therapy (PO-SACT) features on outcomes is lacking. Methods: For this real-world evidence study, we used prospectively collected data within the international surgical LiverMetSurvey database from all patients with initially-irresectable CLM. The main outcome was Overall Survival (OS) after surgery. Disease-free (DFS) and hepatic-specific relapse-free survival (HS-RFS) were secondary outcomes. PO-SACT features included duration (cumulative number of cycles), choice of the cytotoxic backbone (oxaliplatin- or irinotecan-based), fluoropyrimidine (infusional or oral) and addition or not of targeted monoclonal antibodies (anti-EGFR or anti-VEGF). Results: A total of 2793 patients in the database had received PO-SACT for initially irresectable diseases. Short (<7 or <13 cycles in 1st or 2nd line) PO-SACT duration was independently associated with longer OS (HR: 0.85 p = 0.046), DFS (HR: 0.81; p = 0.016) and HS-RFS (HR: 0.80; p = 0.05). All other PO-SACT features yielded basically comparable results. Conclusions: In this international cohort, provided that PO-SACT allowed conversion to resectability in initially irresectable CLM, surgery performed as soon as technically feasible resulted in the best outcomes. When resection was achieved, our findings indicate that the choice of PO-SACT regimen had a marginal if any, impact on outcomes. Background: Prognostic factors have been extensively reported after resection of colorectal liver metastases (CLM); however, specific analyses of the impact of preoperative systemic anticancer therapy (PO-SACT) features on outcomes is lacking. Methods: For this real-world evidence study, we used prospectively collected data within the international surgical LiverMetSurvey database from all patients with initially-irresectable CLM. The main outcome was Overall Survival (OS) after surgery. Disease-free (DFS) and hepatic-specific relapse-free survival (HS-RFS) were secondary outcomes. PO-SACT features included duration (cumulative number of cycles), choice of the cytotoxic backbone (oxaliplatin- or irinotecan-based), fluoropyrimidine (infusional or oral) and addition or not of targeted monoclonal antibodies (anti-EGFR or anti-VEGF). Results: A total of 2793 patients in the database had received PO-SACT for initially irresectable diseases. Short (<7 or <13 cycles in 1st or 2nd line) PO-SACT duration was independently associated with longer OS (HR: 0.85 p = 0.046), DFS (HR: 0.81; p = 0.016) and HS-RFS (HR: 0.80; p = 0.05). All other PO-SACT features yielded basically comparable results. Conclusions: In this international cohort, provided that PO-SACT allowed conversion to resectability in initially irresectable CLM, surgery performed as soon as technically feasible resulted in the best outcomes. When resection was achieved, our findings indicate that the choice of PO-SACT regimen had a marginal if any, impact on outcomes.
publishDate 2022
dc.date.none.fl_str_mv 2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://i3pt.portalinvestigacion.com/publicaciones/1260
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85137942737&doi=10.3390%2fcancers14174340&partnerID=40&md5=df8379f0a2b3fbb33fa86cf11cb98b00
url https://i3pt.portalinvestigacion.com/publicaciones/1260
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85137942737&doi=10.3390%2fcancers14174340&partnerID=40&md5=df8379f0a2b3fbb33fa86cf11cb98b00
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv Cancers
ISSN: 20726694
reponame:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
instname:Institut d'Investigació i Innovació Parc Taulí (I3PT)
instname_str Institut d'Investigació i Innovació Parc Taulí (I3PT)
reponame_str r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
collection r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869409604262166528
spelling Impact of Preoperative Chemotherapy Features on Patient Outcomes after Hepatectomy for Initially Unresectable Colorectal Cancer Liver Metastases: A LiverMetSurvey AnalysisInnominato, PFCailliez, VAllard, MALopez-Ben, SFerrero, AMarques, HHubert, CGiuliante, FPereira, FCugat, EMirza, DFCosta-Maia, JSerrablo, ALapointe, RDopazo, CTralhao, JKaiser, GChen, JSGarcia-Borobia, FRegimbeau, JMSkipenko, OLin, JKLaurent, COpocher, EGoto, YChibaudel, Bde Gramont, AAdam, Rcolorectal cancerliver metastaseshepatectomyneo-adjuvant chemotherapypreoperative chemotherapyonco-surgical approachliver resectionLiverMetSurveyreal-world evidencedownsizingirresectable hepatic metastasesSimple Summary The features of preoperative systemic anticancer therapy associated with best outcomes after resection of initially-irresectable liver metastases from colorectal cancer are yet to be identified. We harnessed data from a prospective international surgical database (LiverMetSurvey) to explore the duration and modalities of preoperative systemic anticancer therapy associated with longer overall survival in this clinical setting. Our study included 2793 patients having undergone liver surgery after preoperative systemic anticancer treatment for initially irresectable disease. We found that short (<7 or <13 cycles in 1st or 2nd line, respectively) duration was associated with longer survival outcomes, independently from other prognostic factors. Conversely, all the comparisons between different conventional active regimens displayed similar results. Our findings support the recommended onco-surgical approach of aiming at performing liver surgery as soon as technically feasible after response to preoperative systemic anticancer therapy in hepatic metastases from colorectal cancer, initially not amenable to surgery. The results of this study also suggest that, provided the systemic anticancer therapy regimen is active, the choice of the drugs used bears overall little if any impact on the outcomes. Background: Prognostic factors have been extensively reported after resection of colorectal liver metastases (CLM); however, specific analyses of the impact of preoperative systemic anticancer therapy (PO-SACT) features on outcomes is lacking. Methods: For this real-world evidence study, we used prospectively collected data within the international surgical LiverMetSurvey database from all patients with initially-irresectable CLM. The main outcome was Overall Survival (OS) after surgery. Disease-free (DFS) and hepatic-specific relapse-free survival (HS-RFS) were secondary outcomes. PO-SACT features included duration (cumulative number of cycles), choice of the cytotoxic backbone (oxaliplatin- or irinotecan-based), fluoropyrimidine (infusional or oral) and addition or not of targeted monoclonal antibodies (anti-EGFR or anti-VEGF). Results: A total of 2793 patients in the database had received PO-SACT for initially irresectable diseases. Short (<7 or <13 cycles in 1st or 2nd line) PO-SACT duration was independently associated with longer OS (HR: 0.85 p = 0.046), DFS (HR: 0.81; p = 0.016) and HS-RFS (HR: 0.80; p = 0.05). All other PO-SACT features yielded basically comparable results. Conclusions: In this international cohort, provided that PO-SACT allowed conversion to resectability in initially irresectable CLM, surgery performed as soon as technically feasible resulted in the best outcomes. When resection was achieved, our findings indicate that the choice of PO-SACT regimen had a marginal if any, impact on outcomes. Background: Prognostic factors have been extensively reported after resection of colorectal liver metastases (CLM); however, specific analyses of the impact of preoperative systemic anticancer therapy (PO-SACT) features on outcomes is lacking. Methods: For this real-world evidence study, we used prospectively collected data within the international surgical LiverMetSurvey database from all patients with initially-irresectable CLM. The main outcome was Overall Survival (OS) after surgery. Disease-free (DFS) and hepatic-specific relapse-free survival (HS-RFS) were secondary outcomes. PO-SACT features included duration (cumulative number of cycles), choice of the cytotoxic backbone (oxaliplatin- or irinotecan-based), fluoropyrimidine (infusional or oral) and addition or not of targeted monoclonal antibodies (anti-EGFR or anti-VEGF). Results: A total of 2793 patients in the database had received PO-SACT for initially irresectable diseases. Short (<7 or <13 cycles in 1st or 2nd line) PO-SACT duration was independently associated with longer OS (HR: 0.85 p = 0.046), DFS (HR: 0.81; p = 0.016) and HS-RFS (HR: 0.80; p = 0.05). All other PO-SACT features yielded basically comparable results. Conclusions: In this international cohort, provided that PO-SACT allowed conversion to resectability in initially irresectable CLM, surgery performed as soon as technically feasible resulted in the best outcomes. When resection was achieved, our findings indicate that the choice of PO-SACT regimen had a marginal if any, impact on outcomes.MDPI2022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://i3pt.portalinvestigacion.com/publicaciones/1260https://www.scopus.com/inward/record.uri?eid=2-s2.0-85137942737&doi=10.3390%2fcancers14174340&partnerID=40&md5=df8379f0a2b3fbb33fa86cf11cb98b00CancersISSN: 20726694reponame:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulíinstname:Institut d'Investigació i Innovació Parc Taulí (I3PT)Inglésinfo:eu-repo/semantics/openAccessoai:i3pt.fundanetsuite.com:p12602026-06-21T15:30:37Z
score 15,812455

Similares en LA Referencia